Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 5/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.41 |
| ▸ | LTA4H | P09960 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5418561 | 0.91 | TDP1 (0.47) | FFAR1FFAR4LTB4RLTA4HTDP1 | |
| SCHEMBL5399151 | 0.91 | LTB4R (0.42) | LTB4RLTB4R2TDP1MEN1KMT2A | |
| SCHEMBL5407120 | 0.90 | KMT2A (0.41) | LTB4RLTB4R2TDP1MEN1KMT2A | |
| SCHEMBL5399037 | 0.88 | TRPM8 (0.39) | FFAR1FFAR4LTA4HTDP1MEN1 | |
| SCHEMBL5392301 | 0.87 | MEN1 (0.41) | TDP1MEN1KMT2APOLB | |
| SCHEMBL5402495 | 0.87 | POLB (0.44) | LTB4RLTB4R2TDP1MEN1KMT2A | |
| SCHEMBL5400818 | 0.86 | MEN1 (0.39) | TDP1MEN1KMT2ATRPM8POLB | |
| SCHEMBL5404063 | 0.85 | KDM4A (0.40) | LTB4RLTB4R2TDP1MEN1KMT2A | |
| SCHEMBL5398199 | 0.85 | MEN1 (0.44) | LTA4HTDP1MEN1KMT2ARAB9A | |
| SCHEMBL5398741 | 0.84 | CA1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285680-B2 | β-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1533294-A1 | BETA-ALANINE DERIVATIVE AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | TGFB1, PML, APOB | FFAR1 65/4885FFAR4 187/4885LTB4R 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.